This study evaluated a simplified outpatient ramp-up dosing and monitoring strategy for investigational sonrotoclax when combined with zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (TN CLL).
This phase 1/2 study included 2 parts in the TN CLL cohort: part 1 assessed sonrotoclax ramp-up schedule safety in a patient subset before expansion in part 2. Treatment started with 3 cycles (28 days each) of zanubrutinib lead-in (160 mg twice daily or 320 mg once daily). Sonrotoclax was initiated in the outpatient setting on cycle 4 day 1 with weekly ramp-up (2, 5, 20, and 80 mg once daily), reaching the 320 mg once daily target dose after 4 weeks. Combination treatment continued for 12 cycles. Tumor lysis syndrome (TLS) risk was assessed at screening and at the end of zanubrutinib lead-in; TLS prophylaxis included oral hydration and antihyperuricemic agents. TLS monitoring included vital signs and serum chemistry ≤4 hours before and 4-6 hours after the first sonrotoclax dose and each dose increase. The primary endpoint was TLS incidence (per Howard criteria) during the schedule-limiting toxicity (SLT) evaluation window (from initial sonrotoclax dose until 7 days after target dose). Secondary endpoints were safety and tolerability, including treatment-emergent adverse events (TEAEs) and dose modifications during SLT evaluation.
A total of 56 patients with TN CLL completed SLT observation and were evaluable for the primary endpoint (part 1: n=6; part 2: n=50). Median age was 64.5 years (range, 35-80); 71% were male and 82% were White. Forty-four patients (79%) had Binet stage B or C. Twenty-seven percent had high tumor burden (any lymph node ≥10 cm or any lymph node ≥5 cm with ALC ≥25×10⁹/L), 48% had unmutated immunoglobulin heavy chain variable region (IGHV) gene, 11% had TP53 mutation (variant allele frequency [VAF] ≥10%), and 7% had del(17p). Median absolute lymphocyte count (ALC) was 100.8×10⁹/L (range, 3.8-351.8×10⁹/L). Median study follow-up was 6.3 months (range, 4.7-14.5 months).
No laboratory or clinical cases of tumor lysis syndrome occurred among 56 SLT-evaluable patients. Transient grade 1 hyperphosphatemia (phosphate levels, 1.52-1.69 mmol/L) was observed in 9 patients post-dose across all ramp-up levels; none required medical intervention or sonrotoclax dose modification. No other TLS-related laboratory abnormalities (e.g., hyperkalemia or hyperuricemia) were observed within the SLT period.
With median study follow-up of 6.3 months (range, 4.7-14.5 months), no TEAEs led to treatment discontinuation or dose reduction of either study drug. The most common any-grade TEAEs were bruising (39%), neutropenia (20%), arthralgia (20%), diarrhea (20%), and headache (20%). Neutropenia (14%) was the only grade ≥3 TEAE occurring in ≥5% of patients. No TEAEs led to death.